US EditionAssessing Post-Treatment MRI for Predicting Neoadjuvant Chemoimmunotherapy Response for Triple-Negative Breast Cancer
Summary by diagnosticimaging.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
All
Left
Center
Right
Stuttgart – Experts are still debating the optimal surgical staging procedure for axillary cancer patients who have converted from an initial node-positive (cN+) to a negative status (ycNo) after neoadjuvant chemotherapy (NACT). The goal of the AXSANA study is to compare different techniques...
Assessing Post-Treatment MRI for Predicting Neoadjuvant Chemoimmunotherapy Response for Triple-Negative Breast Cancer
In external testing, a model combining radiological complete response on breast MRI, nodal status and Ki-67 proliferation index yielded an 88 percent AUC for predicting pathologic complete response to neoadjuvant chemoimmunotherapy for patients with triple-negative breast cancer, according to new research.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
